Company Overview: Celsion

Industry News

27 Feb

Celsion Presents Two Posters on its GEN-1 IL-12 Gene-Mediated Immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium

LAWRENCEVILLE, N.J., Feb. 27, 2017 (GLOBE NEWSWIRE) — Celsion Corporation (CLSN) today announced that Khursheed Anwer, Ph.D., Celsion’s executive vice president and chief science officer, presented two posters on February 23, 2017 at the American Society of Clinical Oncology (ASCO) – Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium...

Read more

21 Feb

Celsion Corp. Cancer Medications Insider Buying and Analysis

NEW YORK, NY / ACCESSWIRE / February 21, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and micro-cap public companies, is covering Celsion Corp. (CLSN) today, in light of recent insider buying. In the recent past, Celsion reported several Insider...

Read more

19 Jan

Celsion to Present Two Posters on its GEN-1 IL-12 Gene-Mediated Immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium

LAWRENCEVILLE, N.J., Jan. 19, 2017 (GLOBE NEWSWIRE) — Celsion Corporation (CLSN) today announced that it will present two posters at the American Society of Clinical Oncology (ASCO) – Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium being held from February 23 – 25, 2017 in Orlando, FL.  The symposium...

Read more

18 Jan

Celsion Corporation Announces Issuance of Two New Patents for ThermoDox®

LAWRENCEVILLE, N.J., Jan. 18, 2017 (GLOBE NEWSWIRE) — Celsion Corporation (CLSN), a clinical stage oncology drug development company, today announced that the United States Patent and Trademark Office has granted U.S Utility Patent No. 9,492,385 B2 – Temperature-Sensitive Liposomal Formulation, which is directly applicable to the method of treating...

Read more

17 Jan

Celsion Announces Continuing Positive Data from the OVATION Study in Newly Diagnosed Advanced Ovarian Cancer Patients

LAWRENCEVILLE, N.J., Jan. 17, 2017 (GLOBE NEWSWIRE) — Celsion Corporation (CLSN) today announced data from the fourth cohort of patients in its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company’s IL-12 gene-mediated immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with...

Read more

30 Nov

Celsion Announces Data Monitoring Committee Unanimously Recommends Continuation of Phase III OPTIMA Study of ThermoDox® for Primary Liver Cancer

LAWRENCEVILLE, N.J., Nov. 30, 2016 (GLOBE NEWSWIRE) — Celsion Corporation (CLSN) today announced that following a review of data from its multinational, randomized pivotal Phase III clinical study of ThermoDox® in combination with optimized radiofrequency ablation (RFA) for primary liver cancer (the OPTIMA Study), the study’s Data Monitoring Committee (DMC)...

Read more

29 Nov

Celsion Corporation Announces Presentation of Results from Independent NIH Analysis of ThermoDox® plus Optimized RFA for the Treatment of Primary Liver Cancer at the 2016 RSNA Annual Meeting

LAWRENCEVILLE, N.J., Nov. 29, 2016 (GLOBE NEWSWIRE) — Celsion Corporation (CLSN) today announced the presentation of results from an independent retrospective analysis conducted by the National Institutes of Health (NIH) on the intent-to-treat population of the Company’s HEAT Study, a 701-patient study of ThermoDox®, Celsion’s proprietary heat-activated liposomal encapsulation of...

Read more

Page 1 of 41234

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address